Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CBF-AML + These Gene Defects = Poor Outcomes

Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 25; Kahn, et al

Patients with relapsed core binding factor acute myeloid leukemia (CBF-AML) who have certain genetic abnormalities tend to experience short survival, according to a retrospective analysis involving 92 individuals. Outcomes are particularly worse for those with the t (8; 21) abnormality. Investigators looked at overall survival in participants treated at a single institution between 1990 and 2014. Among the results:

  • ~Two-thirds of patients had inv (16) and the remainder t (8; 21) abnormalities.
  • Median survival for the inv (16) group was 15.6 months, vs 9 months in the t (8;21) contingent.
  • Increased age, high white blood cell count, t (8; 21) cytogenetic group, and high bone marrow blast percentage were linked with poor overall outcome.
  • Stem cell transplant was linked with better survival.
  • Additional cytogenetic aberrations at relapse were not linked with survival outcomes.
  • Patients with t (8;21) abnormalities were 80% more likely to die after adjusting for certain variables.


Kahn M, Cortes J, Quio W, et al. Outcomes of patients with relapsed core binding factor-positive acute myeloid leukemia. [Published online ahead of print September 25, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.09.017.